Viewing nowCombinationMaxevica Tablets 5/40 Milligrams
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Macnulty Pharmaceutical Co., Ltd.

MFDS item code 201902139 · Approved 2019.04.08 · Insurance code 641502390
Treatment of essential hypertension not controlled with monotherapy
This medicine is used to effectively lower the blood pressure of patients with essential hypertension that is not adequately controlled with monotherapy of amlodipine or olmesartan medoxomil. Managing hypertension is crucial for preventing cardiovascular diseases, and this medication helps maintain stable blood pressure in patients. It aids in enhancing treatment efficacy according to the patient's blood pressure condition and reduces the risk of complications. Ultimately, it contributes to effectively managing hypertension for a healthier lifestyle.
Take 1 tablet once daily with water, with or without food. It is recommended that you take it at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose of the individual components (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not adequately controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced intravascular effective circulating volume: In patients who may have reduced intravascular effective circulating volume (Intravascular volume depletion) (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medicine must not be administered to patients with severe hepatic impairment. (See Precautions for Use, 2. Patients Who Must Not Be Administered This Medicine.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
Pediatric patients younger than 18 years: Safety and efficacy have not been established.
This medication can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. It should not be administered to individuals with allergies to the active ingredients or similar substances, pregnant or breastfeeding women, patients with severe liver dysfunction, aortic stenosis, biliary obstruction, kidney dialysis patients, patients in shock, and certain diabetic patients. Patients with low blood pressure due to fluid or salt depletion should be monitored closely at the start of treatment as they may experience too low blood pressure, and appropriate measures should be taken if hypotension occurs. This medication has vasodilatory effects and can cause acute hypotension in some patients, so caution is advised for those with heart valve issues or obstructive coronary artery disease. It should be used with caution in patients with heart failure and may pose a risk of worsening kidney function in patients with impaired kidney function, requiring regular monitoring. Caution is also necessary for patients with decreased liver function, as side effects such as dizziness, headache, hypotension, edema, dyspepsia, and rash may occur; these symptoms should prompt consultation with a physician. This medication is not the same as beta-blockers, but caution is required regarding the risks associated with abruptly discontinuing beta-blockers, and regular checks of blood pressure, kidney function, and electrolyte status are essential. This medication should not be used during pregnancy, and individuals planning to become pregnant or currently pregnant should consult a physician. During breastfeeding, it may be transmitted through breast milk and affect the infant; thus, discontinuing breastfeeding or the medication is recommended. The safety and efficacy of this medication have not been established for children under 18 years of age. Elderly patients may have decreased kidney and liver function, so it is important to start at a low dose and carefully adjust the dosage. In case of overdose, blood pressure may drop excessively, so immediate medical attention is required, and this medication may not be effectively removed by hemodialysis. Store this medication out of the reach of children, protect it from moisture, heat, and direct sunlight, and avoid transferring it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it must be stored in a tightly closed container. It is best to maintain a storage temperature between 1 to 30 degrees Celsius to preserve the medication's effectiveness.
Light yellow round film-coated tablets
30 tablets - 10 tablets/Alu-Alu[*3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Macnulty Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.